Peripheral sensory neuropathy and cisplatin chemotherapy
暂无分享,去创建一个
J. Rogin | R I Roelofs | W Hrushesky | J Rogin | L Rosenberg | W. Hrushesky | R. Roelofs | Leon Rosenberg
[1] E. Wiltshaw,et al. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. , 1976, Cancer treatment reports.
[2] J. Lokich. Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion. , 1980, Cancer treatment reports.
[3] F. Lévi,et al. Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism. , 1982, Cancer treatment reports.
[4] A. Pestronk,et al. Sensory neuropathy in cis-platinum chemotherapy , 1980 .
[5] P. Wiernik,et al. Peripheral neuropathy after cis-platinum (II) (DDP) therapy. , 1980, Archives of physical medicine and rehabilitation.
[6] M. Cohen,et al. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: a case report. , 1978, Cancer treatment reports.
[7] N. Bachur,et al. Cis‐dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms , 1980, Cancer.
[8] V. Wolfe,et al. Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. , 1974, Cancer chemotherapy reports.
[9] J. Kovach,et al. Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. , 1973, Cancer chemotherapy reports.
[10] S. Wallace,et al. Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy , 1980, Cancer.
[11] F. Lévi,et al. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. , 1982, Cancer research.
[12] J. Wharton,et al. Single-Agent cis-Platinum Therapy for Advanced Ovarian Cancer , 1981, Obstetrics and gynecology.
[13] F. Lévi,et al. Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. , 1982, Cancer research.
[14] E. Cho,et al. A single intravenous injection of doxorubicin (Adriamycin®) induces sensory neuronopathy in rats , 1980 .
[15] E. Cvitkovic,et al. cis-Platinum ototoxicity. , 1978, Clinical toxicology.
[16] F. Lévi,et al. Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration. , 1982, European journal of cancer & clinical oncology.
[17] L. Davis,et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies , 1984, Cancer.
[18] R. Priore,et al. Auditory toxicity effects of long‐term cis‐dichlorodiammineplatinum II therapy in genitourinary cancer patients , 1981, Journal of Surgical Oncology.
[19] J. Holland,et al. Diamminodichloroplatinum in the chemotherapy of testicular tumors. , 1974, The Journal of urology.